Multiple‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Overweight and Obese Subjects: A Randomized Double‐Blind Study
- 1 June 2010
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 50 (6) , 636-646
Abstract
Sergliflozin, the active entity of sergliflozin etabonate, is a selective inhibitor of the sodium‐dependent glucose cotransporter‐2 in the renal tubule. The pharmacokinetics and pharmacodynamics of sergliflozin were examined during administration of sergliflozin etabonate (500 or 1000 mg) or placebo 3 times daily (tid) for 14 days in healthy overweight or obese human volunteers (n = 18). At the doses tested, sergliflozin showed less than dose‐proportional pharmacokinetic characteristics. Mean half‐life of the active entity was approximately 2 hours; there was no evidence of drug accumulation. Sergliflozin etabonate produced rapid and sustained suppression of renal glucose reabsorption, resulting in a dose‐related glucosuria, and a transient increase in urinary electrolyte and fluid loss; plasma glucose, insulin, and electrolyte levels were unchanged. Sergliflozin etabonate produced a rapid, dose‐related reduction in body weight (mean changes of −0.09, −1.55, and −1.74 kg from baseline to day 15 with placebo, sergliflozin etabonate 500 mg, and sergliflozin etabonate 1000 mg, respectively), apparently through increased urinary calorie loss rather than through osmotic diuresis. Sergliflozin etabonate 500 or 1000 mg tid was generally well tolerated; no clinically significant adverse events were identified. Renal function (creatinine clearance) was not affected by sergliflozin etabonate, although urinary microalbumin, N‐acetyl‐beta‐D‐glucosaminidase, and β2‐microglobulin levels tended to increase.Keywords
This publication has 21 references indexed in Scilit:
- Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty ratsEuropean Journal of Pharmacology, 2009
- Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose LevelThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wastingKidney International, 2006
- Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agentsExpert Opinion on Therapeutic Patents, 2005
- Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetesDiabetes & Metabolism, 2005
- Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)Human Genetics, 2002
- Updated review on the benefits of weight lossInternational Journal of Obesity, 2002
- Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1Diabetes/Metabolism Research and Reviews, 2002
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.Journal of Clinical Investigation, 1994